Literature DB >> 26541358

Synthetic Tet-inducible artificial microRNAs targeting β-catenin or HIF-1α inhibit malignant phenotypes of bladder cancer cells T24 and 5637.

Yonghao Zhan1,2, Yuchen Liu1, Junhao Lin1,2, Xing Fu1, Chengle Zhuang1,2, Li Liu1,2, Wen Xu1,3, Jianfa Li1,2, Mingwei Chen1, Guoping Zhao4, Weiren Huang1, Zhiming Cai1.   

Abstract

Ribonucleic acid interference (RNAi) based on microRNA (miRNA) may provide efficient and safe therapeutic opportunities. However, natural microRNAs can not easily be regulated and usually cause few phenotypic changes. Using the engineering principles of synthetic biology, we provided a novel and standard platform for the generation of tetracycline (Tet)-inducible vectors that express artificial microRNAs in a dosage-dependent manner. The vector generates a Pol II promoter-mediated artificial microRNA which was flanked by ribozyme sequences. In order to prove the utility of this platform, we chose β-catenin and HIF-1α as the functional targets and used the bladder cancer cell lines 5637 and T24 as the test models. We found that the Tet-inducible artificial microRNAs can effectively silence the target genes and their downstream genes, and induce anti-cancer effects in the two bladder cancer cell lines. These devices can inhibit proliferation, induce apoptosis, and suppress migration of the bladder cancer cell lines 5637 and T24. The Tet-inducible synthetic artificial microRNAs may represent a kind of novel therapeutic strategies for treating human bladder cancer.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26541358      PMCID: PMC4635424          DOI: 10.1038/srep16177

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


Urothelial bladder cancer is difficult to treat with current therapies such as surgery, radiation therapy, and chemotherapy12. Therefore, it is necessary to develop a more efficient and safer therapeutic method for treating urothelial bladder cancer. RNA interference (ribonucleic acid interference, RNAi) is a powerful tool that blocks gene expression in mammalian cells by triggering sequence-specific gene degradation during posttranscriptional gene silencing34. It has been reported that natural microRNAs and designed shRNA are useful to treat bladder cancer56. However, microRNAs usually cause few phenotypic changes due to the divergent functions of their target genes7. Although shRNA transcribed by RNA polymerase III (Pol III) promoter (e.g., U6 or H1 promoter) can be used to effectively silence gene expression, long-term suppression could be problematic and natural Pol III could not easily be used to directly response to external ligands8. Medical synthetic biology is an emerging field that combines engineering principles with biology to achieve the design and production of new artificial devices for controlling complex biological phenotypes of living organisms91011. Using the engineering principles of medical synthetic biology, we provided a novel and standard platform for the generation of tetracycline (Tet)-inducible vectors that express artificial microRNAs in a dosage-dependent manner12. Furthermore, we attached an artificial gene named RGR to the artificial microRNA that, once transcribed, generates an RNA molecule with ribozyme sequences at both ends of the designed artificial microRNA. The primary transcripts of RGR undergo self‐catalyzedcleavage to precisely release the designed artificial microRNA mediated by Pol II promoters13. Our results demonstrated that the Tet-inducible artificial microRNAs targeting β-catenin and HIF-1α can effectively inhibit malignant phenotypes of bladder cancer cells in a dosage-dependent manner.

Results

Design and construct the optimized Tet-inducible artificial microRNAs

We set out to construct the Tet-inducible artificial microRNAs that target β-catenin or HIF-1α mRNAs. To silence β-catenin or HIF-1α mRNAs, the RNAi sequence of β-catenin or HIF-1α (shRNA-β-catenin or shRNA-HIF-1α) was used to replace the mature-miR-30 encoding region of pre-miR-30 scaffold. Then we got the “amiRNA β-catenin” and “amiRNA HIF-1α”. Similarly, the negative control sequence was also constructed by using the sequence of shRNA-NC to replace the corresponding region of pre-miR-30 scaffold. Then we linked the artificial microRNA with an artificial gene named RGR and generated an RNA molecule with ribozyme sequences at both ends of the designed artificial microRNA. The primary transcripts of RGR undergo self-catalyzed cleavage to precisely release the designed artificial microRNA. All the related sequences are shown in Table 1. Then we inserted the related sequences into the linearized Tet-on vector (PEV-Lv208) containing RNA Pol II promoter for expression of protein-coding genes and got the Tet-inducible amiRNA systems.
Table 1

Artificial MicroRNA Sequences in the Vector.

NameArtificial MicroRNA Sequence
amiRNA β-cateninTACCTTCTGATGAGTCCGTGAGGACGAAACGAGTAAGCTCGTCAAGGTATATTGCTGTTGACAGTGAGCGCAAACAGTCTTACCTGGACTCTGATAGTGAAGCCACAGATGTATCAGAGTCCAGGTAAGACTGTTTTTGCCTACTGCCTCGGGCCGGCATGGTCCCAGCCTCCTCGCTGGCGCCGGCTGGGCAACATGCTTCGGCATGGCGAATGGGAC
amiRNA HIF-1αTACCTTCTGATGAGTCCGTGAGGACGAAACGAGTAAGCTCGTCAAGGTATATTGCTGTTGACAGTGAGCGCAGATGCTTACACACAGAAATGATAGTGAAGCCACAGATGTATCATTTCTGTGTGTAAGCATCTTTGCCTACTGCCTCGGGCCGGCATGGTCCCAGCCTCCTCGCTGGCGCCGGCTGGGCAACATGCTTCGGCATGGCGAATGGGAC
amiRNA-NCTACCTTCTGATGAGTCCGTGAGGACGAAACGAGTAAGCTCGTCAAGGTATATTGCTGTTGACAGTGAGCGCATTCTCCGAACGTGTCACGTATAGTGAAGCCACAGATGTATACGTGACACGTTCGGAGAATTTGCCTACTGCCTCGGGCCGGCATGGTCCCAGCCTCCTCGCTGGCGCCGGCTGGGCAACATGCTTCGGCATGGCGAATGGGAC

The effects of Tet-inducible artificial microRNAs on the expression levels of the target genes and their downstream genes in bladder cancer cells

We transfected the plasmids expressing either the corresponding Tet-inducible artificial microRNA or the negative control into bladder cancer cells, and examined the expression levels of the targeted genes and their downstream genes in these cells. We measured the relative expression level of β-catenin mRNA/HIF-1α mRNA by using qRT-PCR at 48 h post-transfection. The “amiRNA β-catenin” induced by doxycycline could inhibit the expression level of β-catenin mRNA in T24 (Fig. 1A) and 5637 (Fig. 1B). Similarly, the “amiRNA HIF-1α” induced by doxycycline could reduce the expression level of HIF-1α mRNA in T24 (Fig. 1C) and 5637 (Fig. 1D). These results showed substantial dose-dependent repression upon induction with doxycycline. Because both β-catenin and HIF-1α function as transcriptional activators, we wanted to know whether the constructed amiRNAs could inhibit mRNA expression of their downstream genes. We examined the relative gene expression levels in the amiRNAs-transfected bladder cancer cell lines and the mRNA levels of c-Myc (Fig. 2A,B), cyclin D1 (Fig. 2A,B), IGF2 (Fig. 2C,D), and VEGF (Fig. 2C,D) were down-regulated by the corresponding amiRNA in the bladder cell lines.
Figure 1

The effects of Tet-inducible artificial microRNAs on the expression levels of their target genes in bladder cancer cells.

The relative expression levels of β-catenin (A,B) and HIF-1α (C,D) were evaluated using qRT-PCR. Data are shown as mean ± SD.

Figure 2

The effects of Tet-inducible artificial microRNAs on the expression levels of the downstream genes in bladder cancer cells.

The relative expression levels of c-Myc (A,B), cyclin D1 (A,B), IGF2 (C,D) and VEGF (C,D) were evaluated using qRT-PCR. Data are shown as mean ± SD.

The effects of Tet-inducible artificial microRNAs on cell proliferation in bladder cancer cells

We transfected the plasmids expressing either the corresponding Tet-inducible artificial microRNA or the negative control into bladder cancer cells, and examined cell wproliferation. In CCK-8 assays, we demonstrated that the “amiRNA β-catenin” induced by doxycycline (Fig. 3A,B) or the “amiRNA HIF-1α” induced by doxycycline (Fig. 3C,D) effectively reduced cell proliferation when compared with the negative control group. EdU incorporation assays were then used as a further study to determine the effects of amiRNAs on proliferation of bladder cancer cell lines. The results showed that amiRNAs induced by doxycycline could inhibit the cancer cell growth remarkably (Fig. 3E,F).
Figure 3

The effects of Tet-inducible artificial microRNAs on cell proliferation in bladder cancer cells.

The growth curves of T24/5637 cells treated with “amiRNA β-catenin” (A,B) or “amiRNA HIF-1α” (C,D) induced by doxycycline were determined using CCK-8 assay. Data are shown as mean ± SD. The proliferation of T24 (E) and 5637 (F) treated with “amiRNA β-catenin” or “amiRNA HIF-1α” induced by doxycycline were also determined using EdU incorporation assay.

The effects of Tet-inducible artificial microRNAs on cell apoptosis in bladder cancer cells

We transfected the plasmids expressing the corresponding Tet-inducible artificial microRNA or the negative control into bladder cancer cells, and examined cell apoptosis. The relative activity of caspase-3 was determined using ELISA assay and the apoptosis ratio in bladder cancer cells was measured using Hoechst 33258 staining. The relative activity of caspase-3 were dramatically elevated when cells were treated with the “amiRNA β-catenin” induced by doxycycline (Fig. 4A,B) or the “amiRNA HIF-1α” induced by doxycycline (Fig. 4A,B). These findings were also confirmed by analyzing the apoptosis ratio (Fig. 4C–F).
Figure 4

The effects of Tet-inducible artificial microRNAs on cell apoptosis in bladder cancer cells.

The relative activity of caspase-3 was calculated in T24/5637 cells treated with “amiRNA β-catenin” (A,B) or “amiRNA HIF-1α” (A,B) induced by doxycycline using ELISA assay. The apoptotic cells were observed and calculated in T24/5637 cells treated with “amiRNA β-catenin” (C–F) or “amiRNA HIF-1α” (C–F) induced by doxycycline using Hoechst 33258 staining assay. Data are shown as mean ± SD.

The effects of Tet-inducible artificial microRNAs on cell migration in bladder cancer cells

Finally, we treated bladder cancer cells with the Tet-inducible artificial microRNAs and measured cell migration with wound healing assay. Decreased cell motility was observed after transfection of the “amiRNA β-catenin” induced by doxycycline (Fig. 5A,B) or the“amiRNA HIF-1α” induced by doxycycline (Fig. 5A,B).
Figure 5

The effects of Tet-inducible artificial microRNAs on cell migration in bladder cancer cells.

The relative rate of cell migration was calculated in T24 (A) and 5637 (B) cells treated with “amiRNA β-catenin” or “amiRNA HIF-1α” induced by doxycycline using wound-healing assay. Data are shown as mean ± SD.

Discussion

In the past ten years, the community of medical synthetic biology has begun to make great strides in using synthetic biology principles and methodologies to treat human diseases141516. Furthermore, the basic cancer genetic research has made many remarkable achievements1718. Inspired by these exciting works, we proposed that medical synthetic biology can also offer novel solutions to cancer treatment. Based on the engineering principles and methodologies of synthetic biology, we set out to translate the results of basic cancer research and to build complex devices for treating cancers by using existing genetic parts(such as the promoters, terminators, and shRNA/miRNA expression scaffolds)19. The targets of these devices are the cancer-related genes highlighted by the previous works. For example, the gene β-catenin and HIF-1α can be considered to be cancer-related genes and play important roles in the proliferation, apoptosis, and migration of bladder cancer cells by regulating Wnt/β-catenin and HIF-1α pathway, respectively2021. In this study, we constructed the devices (the Tet-inducible artificial microRNAs) and tested their anti-cancer effects. Our results demonstrated that the Tet-inducible artificial microRNAs targeting β-catenin and HIF-1α can be used to effectively silence the cancer-related genes and inhibit malignant phenotypes of bladder cancer cells in a dosage-dependent manner. In conclusion, we have provided a standard synthetic biology platform for constructing Tet-inducible artificial microRNAs that can silence cancer-related genes in a dosage-dependent manner. This work provides a new approach for quantitatively controlling specific targets in human cancer.

Materials and Methods

Cell lines and cell culture

Bladder cancer T24 and 5637 cells used in this study were purchased from the Institute of Cell Research, Chinese Academy of Sciences, Shanghai, China. The 5637 cells were cultured in RPMI-1640 ((Invitrogen, Carlsbad, CA, USA) plus 10% fetal bovine serum. The T24 cells were cultured in DMEM (Invitrogen, Carlsbad, CA, USA) plus 10% fetal bovine serum. Plates were then placed at 37 °C with a humidified atmosphere of 5% CO2 in incubator.

Construction of the optimized Tet-inducible artificial microRNAs

Plasmid vector PEV-Lv208 was purchased from FulenGen, Guangzhou, China. The sequences of the related Tet-inducible artificial microRNAs and the negative control were designed and chemically synthesized. These synthetic related sequences were inserted into PEV-Lv208 vector at the restriction sites of BamHI/XhoI. All these vectors were then transformed into E. coli, and the positive clones were identified by electrophoresis and confirmed by Sanger sequencing. Thorough descriptions of the related Tet-inducible artificial microRNA sequences are presented in Table 1.

Cell transfection

The cells were cultured 24 h prior to transfection. Then, the cells were transiently transfected with the synthetic devices using Lipofectamine 2000 Transfection Reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s instructions.

RNA extraction and qRT-PCR

At forty-eight hours post-transfection, 1 × 106 cells were collected and the total RNA of different groups were extracted using the Trizol reagent (Invitrogen, USA) according to the manufacturer’s protocol. The concentration and purity of the total RNA were detected with UV spectrophotometer analysis at 260 nm. Synthesis of cDNA was performed by using SuperScript III® (Invitrogen) according to the manufacturer’s instructions. Quantitative real-time PCR was performed using the ABI PRISM 7000 Fluorescent Quantitative PCR System (Applied Biosystems, Foster City, CA, USA) according to the manufacturer’s instructions. Expression fold changes were calculated using 2−ΔΔCt methods.

Cell proliferation assay

Cell proliferation was determined using Cell Counting Kit-8 (Beyotime Inst Biotech, China) according to manufacture’s instructions. Briefly, 5 × 103 cells/well were seeded in a 96-well flat-bottomed plate, and grown at 37 °C for 24 h. At 24, 48, 72 hours after transfection, 10 μl of CCK-8 (5 mg/ml) was added to each well of a 96-well plate and the cells were cultured for 1 hour. The absorbance was finally determined at a wavelength of 450 nm using an ELISA microplate reader (Bio-Rad, Hercules, CA, USA). Experiments were repeated at least three times. Cell proliferation was also determined by Ethynyl-2-deoxyuridine incorporation assay using the corresponding kit (Beyotime Inst Biotech, China). Briefly, 1 × 105 cells/well were seeded in a 96-well flat-bottomed plate, and incubated with 100 μl of 50 μM EdU per well for 2 h. Then, the cells were fixed for 30 min at room temperature by using 50 μl of fixing buffer. After removing the buffer, the cells were incubated with 50 μl of 2 mg/ml glycine for 5 min followed by washing with 100 μl of PBS. The cells in each well were then added with 100 μl of permeabilization buffer followed by washing with 100 μl of PBS. Subsequently, cells were added with 100 μl of 1X Apollo solution for 30 min at room temperature in the dark. After that, cells were incubated with 100 μl of 1X DAPI solution for 30 min at room temperature in the dark followed by washing with 100 μl of PBS. The cells were then observed using fluorescence microscopy.

Cell apoptosis assay

Cell apoptosis was revealed by both Hoechst 33258 staining assay and ELISA assay. Apoptosis ratio in bladder cancer cells was measured using Hoechst 33258 staining kit (Beyotime, Shanghai, China), and Caspase-3 activity was measured using a Caspase-3 Colorimetric Assay kit (Abcam, Cambridge, UK) according to the manufacturer’s instructions at 48 hours after transfection. Experiments were repeated at least three times in duplicates.

Cell motility assay

Cell motility was determined by wound-healing assay. A wound field was created using a sterile 200 μl pipette tip in about 90% confluent cells. The migration of cells was monitored with a digital camera system. The cell migration distance (μm) was calculated by the software program HMIAS-2000, at 24 hours after transfection. These experiments were repeated at least three times.

Statistical analyses

All experimental data from three independent experiments were analyzed by Student’s t-test or ANOVA and P < 0.05 was considered statistically significant. All statistical tests were conducted by SPSS version 19.0 software (SPSS Inc. Chicago, IL, USA).

Additional Information

How to cite this article: Zhan, Y. et al. Synthetic Tet-inducible artificial microRNAs targeting β-catenin or HIF-1α inhibit malignant phenotypes of bladder cancer cells T24 and 5637. Sci. Rep. 5, 16177; doi: 10.1038/srep16177 (2015).
  21 in total

1.  RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals.

Authors:  P D Zamore; T Tuschl; P A Sharp; D P Bartel
Journal:  Cell       Date:  2000-03-31       Impact factor: 41.582

Review 2.  Rnai as an experimental and therapeutic tool to study and regulate physiological and disease processes.

Authors:  Christopher P Dillon; Peter Sandy; Alessio Nencioni; Stephan Kissler; Douglas A Rubinson; Luk Van Parijs
Journal:  Annu Rev Physiol       Date:  2005       Impact factor: 19.318

Review 3.  The role of radiotherapy in urinary bladder cancer: current status.

Authors:  Gustavo Nader Marta; Samir Abdallah Hanna; Rafael Gadia; Sebastiao Francisco Miranda Correa; Joao Luis Fernandes da Silva; Heloisa de Andrade Carvalho
Journal:  Int Braz J Urol       Date:  2012 Mar-Apr       Impact factor: 1.541

4.  Self-processing of ribozyme-flanked RNAs into guide RNAs in vitro and in vivo for CRISPR-mediated genome editing.

Authors:  Yangbin Gao; Yunde Zhao
Journal:  J Integr Plant Biol       Date:  2014-03-06       Impact factor: 7.061

Review 5.  RNA interference and its role in cancer therapy.

Authors:  Behzad Mansoori; Siamak Sandoghchian Shotorbani; Behzad Baradaran
Journal:  Adv Pharm Bull       Date:  2014-08-10

6.  Specific inhibition of gene expression using a stably integrated, inducible small-interfering-RNA vector.

Authors:  Marc van de Wetering; Irma Oving; Vanesa Muncan; Menno Tjon Pon Fong; Helen Brantjes; Dik van Leenen; Frank C P Holstege; Thijn R Brummelkamp; Reuven Agami; Hans Clevers
Journal:  EMBO Rep       Date:  2003-06       Impact factor: 8.807

Review 7.  MicroRNAs and cancer: current state and future perspectives in urologic oncology.

Authors:  Annika Schaefer; Monika Jung; Glen Kristiansen; Michael Lein; Mark Schrader; Kurt Miller; Carsten Stephan; Klaus Jung
Journal:  Urol Oncol       Date:  2008-12-30       Impact factor: 3.498

8.  Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases.

Authors:  H Zhong; A M De Marzo; E Laughner; M Lim; D A Hilton; D Zagzag; P Buechler; W B Isaacs; G L Semenza; J W Simons
Journal:  Cancer Res       Date:  1999-11-15       Impact factor: 12.701

Review 9.  MicroRNAs as potential biomarkers in cancer: opportunities and challenges.

Authors:  Huiyin Lan; Haiqi Lu; Xian Wang; Hongchuan Jin
Journal:  Biomed Res Int       Date:  2015-03-22       Impact factor: 3.411

10.  Lentiviral miR30-based RNA interference against heparanase suppresses melanoma metastasis with lower liver and lung toxicity.

Authors:  Xiao-yan Liu; Qiu-su Tang; Hong-chao Chen; Xiao-ling Jiang; Hong Fang
Journal:  Int J Biol Sci       Date:  2013-06-12       Impact factor: 6.580

View more
  9 in total

1.  Long non-coding RNA ARAP1-AS1 promotes the progression of bladder cancer by regulating miR-4735-3p/NOTCH2 axis.

Authors:  Jingfei Teng; Xing Ai; Zhuomin Jia; Kai Wang; Yawei Guan; Yanjie Guo
Journal:  Cancer Biol Ther       Date:  2018-11-07       Impact factor: 4.742

2.  shRNA targeting long non-coding RNA CCAT2 controlled by tetracycline-inducible system inhibits progression of bladder cancer cells.

Authors:  Jianfa Li; Chengle Zhuang; Yuchen Liu; Mingwei Chen; Qing Zhou; Zhicong Chen; Anbang He; Guoping Zhao; Yinglu Guo; Hanwei Wu; Zhiming Cai; Weiren Huang
Journal:  Oncotarget       Date:  2016-05-17

3.  Increased expression of ZEB1-AS1 correlates with higher histopathological grade and promotes tumorigenesis in bladder cancer.

Authors:  Junhao Lin; Yonghao Zhan; Yuchen Liu; Zhicong Chen; Jianbo Liang; Wei Li; Anbang He; Liqun Zhou; Hongbin Mei; Feng Wang; Weiren Huang
Journal:  Oncotarget       Date:  2017-04-11

Review 4.  Recent development on synthetic biological devices treating bladder cancer.

Authors:  Zhicong Chen; Anbang He; Yuchen Liu; Weiren Huang; Zhiming Cai
Journal:  Synth Syst Biotechnol       Date:  2016-09-14

5.  Up-regulation of long non-coding RNA PANDAR is associated with poor prognosis and promotes tumorigenesis in bladder cancer.

Authors:  Yonghao Zhan; Junhao Lin; Yuchen Liu; Mingwei Chen; Xiaoying Chen; Chengle Zhuang; Li Liu; Wen Xu; Zhicong Chen; Anbang He; Qiaoxia Zhang; Xiaojuan Sun; Guoping Zhao; Weiren Huang
Journal:  J Exp Clin Cancer Res       Date:  2016-05-20

6.  Increased expression of SUMO1P3 predicts poor prognosis and promotes tumor growth and metastasis in bladder cancer.

Authors:  Yonghao Zhan; Yuchen Liu; Chaoliang Wang; Junhao Lin; Mingwei Chen; Xiaoying Chen; Chengle Zhuang; Li Liu; Wen Xu; Qing Zhou; Xiaojuan Sun; Qiaoxia Zhang; Guoping Zhao; Weiren Huang
Journal:  Oncotarget       Date:  2016-03-29

7.  Inhibiting cell migration and cell invasion by silencing the transcription factor ETS-1 in human bladder cancer.

Authors:  Li Liu; Yuchen Liu; Xintao Zhang; Mingwei Chen; Hanwei Wu; Muqi Lin; Yonghao Zhan; Chengle Zhuang; Junhao Lin; Jianfa Li; Wen Xu; Xing Fu; Qiaoxia Zhang; Xiaojuan Sun; Guoping Zhao; Weiren Huang
Journal:  Oncotarget       Date:  2016-05-03

8.  MicroRNA-3713 regulates bladder cell invasion via MMP9.

Authors:  Wen-Bo Wu; Wei Wang; Yi-Heng Du; Hao Li; Shu-Jie Xia; Hai-Tao Liu
Journal:  Sci Rep       Date:  2016-08-31       Impact factor: 4.379

9.  Long non-coding RNA HNF1A-AS1 promotes proliferation and suppresses apoptosis of bladder cancer cells through upregulating Bcl-2.

Authors:  Yonghao Zhan; Yifan Li; Bao Guan; Zicheng Wang; Ding Peng; Zhicong Chen; Anbang He; Shiming He; Yanqing Gong; Xuesong Li; Liqun Zhou
Journal:  Oncotarget       Date:  2017-09-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.